U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H35N5O5
Molecular Weight 581.6628
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERGOTAMINE

SMILES

C[C@@]1(C(=O)N2[C@@]([H])(Cc3ccccc3)C(=O)N4CCC[C@@]4([H])[C@]2(O)O1)N=C([C@]5([H])C=C6c7cccc8c7c(C[C@@]6([H])N(C)C5)c[nH]8)O

InChI

InChIKey=XCGSFFUVFURLIX-VFGNJEKYSA-N
InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1

HIDE SMILES / InChI
The isolation and naming of ergotamine by Stoll occurred in 1925 but the complete elucidation of structure was not achieved until 1951, with synthesis following some 10 years later. Current sources of ergotamine include the isolation from field ergot and fermentation broth, as well as synthesis via coupling of (+)-lysergic acid with the appropriate synthetic peptidic moiety. Ergotamine was introduced into world commerce in 1921, and is currently marketed as its water soluble tartrate salt. Ergotamine is a partial agonist at various tryptaminergic receptors (including the serotonin receptor [5-HT2]) and at various α-adrenergic receptors in blood vessels and various smooth muscles. It is likely that the major activity of ergotamine and related alkaloids is one of agonism at the 5-HT1B/1D receptors, just as with the “triptan” antimigraine compounds. FDA-labeled indications for ergotamine tartrate are in the abortion or prevention of vascular headaches, such as migraine, migraine variant, cluster headache, and histaminic cephalalgia.

Originator

Curator's Comment:: In 1918 Arthur Stoll patented the isolation of ergotamine tartrate, which was subsequently marketed by Sandoz in 1921.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ERGOMAR

Approved Use

Ergomar® is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or a so-called "histaminic cephalalgia".

Launch Date

4.1472E11
Primary
CAFERGOT

Approved Use

Treatment of acute attacks of migraine with or without aura in adults.
Primary
MIGERGOT

Approved Use

MIGERGOT is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called “histaminic cephalalgia.” Ergotamine tartrate and caffeine suppositories should only be used for migraine headaches as they are not effective for other types of headaches and they lack analgesic properties.

Launch Date

4.33987191E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
21.4 pg/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
454 pg/mL
2 mg single, rectal
dose: 2 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.38 ng × h/mL
3.89 μg/kg bw single, intravenous
dose: 3.89 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
61 pg × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.36 ng × h/mL
1.01 μg/kg bw single, intravenous
dose: 1.01 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.04 ng × h/mL
1.94 μg/kg bw single, intravenous
dose: 1.94 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
1216 pg × h/mL
2 mg single, rectal
dose: 2 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.15 h
3.89 μg/kg bw single, intravenous
dose: 3.89 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.08 h
1.01 μg/kg bw single, intravenous
dose: 1.01 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.13 h
1.94 μg/kg bw single, intravenous
dose: 1.94 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
3.35 h
2 mg single, rectal
dose: 2 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea
Vomiting (severe)
Dizziness
Blood pressure decreased
Peripheral vasoconstriction
Paresthesia
Cyanosis peripheral
Angina
Sources:
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Disc. AE: Depression, Vertigo...
AEs leading to
discontinuation/dose reduction:
Depression
Vertigo
Blurred vision
Arrhythmia
Hypersensitivity
Migraine aggravated
Urticaria
Dyspnoea
Fatigue
Tachycardia
Vagal reaction
Dizziness
Tinnitus
Sources: Page: p.319
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources: Page: p.2
unhealthy
n = 41
Health Status: unhealthy
Condition: Migraine
Sex: M+F
Population Size: 41
Sources: Page: p.2
Disc. AE: Nausea, Lightheadedness...
AEs leading to
discontinuation/dose reduction:
Nausea (2.4%)
Lightheadedness (2.4%)
Sources: Page: p.2
AEs

AEs

AESignificanceDosePopulation
Angina Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Blood pressure decreased Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Cyanosis peripheral Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Dizziness Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Nausea Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Paresthesia Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Peripheral vasoconstriction Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Vomiting severe
Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Arrhythmia Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Blurred vision Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Depression Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Dizziness Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Dyspnoea Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Fatigue Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Hypersensitivity Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Migraine aggravated Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Tachycardia Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Tinnitus Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Urticaria Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Vagal reaction Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Vertigo Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Lightheadedness 2.4%
Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources: Page: p.2
unhealthy
n = 41
Health Status: unhealthy
Condition: Migraine
Sex: M+F
Population Size: 41
Sources: Page: p.2
Nausea 2.4%
Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources: Page: p.2
unhealthy
n = 41
Health Status: unhealthy
Condition: Migraine
Sex: M+F
Population Size: 41
Sources: Page: p.2
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Ki 13 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes (co-administration study)
Comment: Coadministration of ergotamine with potent CYP 3A4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities
PubMed

PubMed

TitleDatePubMed
Arterial spasm associated with oral ergotamine therapy.
1973 Dec
Ergotism. Unilateral brachial artery thrombosis secondary to ergotamine tartrate.
1973 Jun
[Acute ischemia of the lower limbs due to ergotamine-induced arteriospasm].
1973 Nov 30
[Chronic ergotamine poisoning after migraine treatment].
1974
Ergotamine-induced venous thrombosis.
1974 Apr
Letter: Rebound migraine.
1974 May 11
Ergot-induced vasospasm of the lower extremities treated with epidural anaesthesia.
1975
[A case of hyposphygmia caused by ergotamine in migraine].
1975 Feb 21
[Is triacetyl oleandomycin-ergotamine tartrate combination dangerous?].
1975 Nov 8
[A case report of acute myocardial infarction induced by ergotamine tartrate (author's transl)].
1981 Mar
Ergotamine abuse: results of ergotamine discontinuation, with special reference to the plasma concentrations.
1982 Dec
Myocardial infarction following administration of sublingual ergotamine.
1982 Sep
[Myocardial infarct during ergotamine medication in a young man with normal coronary arteries].
1983 Apr 22
Screening for new compounds with antiherpes activity.
1984 Oct
Reversible cerebral arteriopathy associated with the administration of ergot derivatives.
1984 Sep
Dystonia and reflex sympathetic dystrophy induced by ergotamine.
1991
Tongue necrosis in temporal arteritis provoked by ergotamine.
1992 Dec
[Migraine caused by ergotamine tartrate dependence].
1992 Jul
Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype.
1992 Jun 15
Severe facial ischaemia caused by ergotism.
1992 May-Jun
Ergotamine-induced headache can be sustained by sumatriptan daily intake.
1994 Oct
Transcranial Doppler ultrasonographic features during drug withdrawal from drug-induced headache. A transcranial Doppler follow-up study.
1998 Oct
Ergotamine-induced intermittent claudication.
1999 May
Ventricular fibrillation secondary to ergotamine in a healthy young woman.
1999 Oct
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
2000 Dec 5
Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.
2000 Jan
Ergotamine in the acute treatment of migraine: a review and European consensus.
2000 Jan
The influence of ergotamine abuse on psychological and cognitive functioning.
2000 Jun
2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors.
2000 Mar 9
Ergotamine, dihydroergotamine: current uses and problems.
2001
Ergotamine-induced acute vascular insufficiency of the lower limb--a case report.
2001 Mar
Successful treatment of threatening limb loss ischemia of the upper limb caused by ergotamine. A case report and review of the literature.
2002 Apr
Fibrotic valvular heart disease subsequent to bromocriptine treatment.
2002 Nov-Dec
[Multifocal brain haemorrhage associated with migraine and medication abuse].
2003 Nov 1-15
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
2004 Aug
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
2004 Jun
[Transient global amnesia following the use of ergots in the treatment of migraine].
2004 Nov 16-30
[Valvular heart disease associated with ergotamine].
2005 Jan
Interactions of metoclopramide and ergotamine with human 5-HT(3A) receptors and human 5-HT reuptake carriers.
2005 Oct
Concurrent moyamoya disease and Graves' thyrotoxicosis: case report and literature review.
2006 Jun
Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period.
2006 May
Pharmacodynamic action and mechanism of volatile oil from Rhizoma Ligustici Chuanxiong Hort. on treating headache.
2009 Jan
Patents

Patents

Sample Use Guides

MIGERGOT - ergotamine tartrate and caffeine rectal suppository. One suppository at start of attack; second suppository after 1 hour, if needed for full relief. Two suppositories is the maximum dose for an individual attack. Cafergot (Ergotamine tartrate 1 mg and Caffeine 100 mg Tablets) First attack: The first time Cafergot is taken, an initial dose of 2 Cafergot tablets orally, is recommended. If relief is not obtained within half an hour, a further tablet should be administered; this may be repeated at half-hourly intervals, but the maximum daily dose of 6 tablets should not be exceeded. Subsequent attacks: If the pain persists, take 1 tablet every half an hour up to the maximum daily dose of 6 tablets. The maximum weekly dose is 10 tablets. ERGOMAR SUBLINGUAL- ergotamine tartrate tablet For best results, dosage should start at the first sign of an attack. Early Administration Gives Maximum Effectiveness. At the first sign of an attack or to relieve symptoms after onset of an attack, one 2 mg tablet is placed under the tongue. Another tablet should be taken at half-hour intervals thereafter, if necessary, but dosage must not exceed three tablets in any 24hour period. Total weekly dosage should not exceed five tablets (10 mg) in any one week. Ergomar® Sublingual Tablets should not be used for chronic daily administration.
Route of Administration: Other
In Vitro Use Guide
The bovine anterior pituitary cells were implanted on culture tubes using D-valine minimal essential medium with serum to suppress the overgrowth of fibroblasts and then maintained in L-valine Dulbecco's modified Eagle medium. (3H)-Uridine uptake by these cells was suppressed by ergotamine at a concentration varing from 1-10 uM
Name Type Language
ERGOTAMINE
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
ERGOTAMINE [HSDB]
Common Name English
ERGOTAMINE [VANDF]
Common Name English
ERGOTAMINE [WHO-DD]
Common Name English
ERGOTAMINE [MI]
Common Name English
ERGOTAMINE [INN]
Common Name English
NSC-95090
Code English
ERGOTAMAN-3',6',18-TRIONE, 12'-HYDROXY-2'-METHYL-5'-(PHENYLMETHYL)-, (5'.ALPHA.)-
Common Name English
Classification Tree Code System Code
NDF-RT N0000007621
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
NCI_THESAURUS C47794
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
NDF-RT N0000007621
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
WHO-ATC N02CA72
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
WHO-VATC QN02CA52
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
WHO-ATC N02CA02
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
LIVERTOX 363
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
NDF-RT N0000175766
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
WHO-ATC N02CA52
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
WHO-VATC QN02CA02
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
WHO-VATC QN02CA72
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
Code System Code Type Description
DRUG CENTRAL
1043
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
INN
391
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
CAS
113-15-5
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
NCI_THESAURUS
C61751
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
EVMPD
SUB06598MIG
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
IUPHAR
149
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
DRUG BANK
DB00696
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
MESH
D004878
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
EPA CompTox
113-15-5
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
FDA UNII
PR834Q503T
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
LACTMED
Ergotamine
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
RXCUI
4025
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M4988
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY Merck Index
PUBCHEM
8223
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
HSDB
4076
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
WIKIPEDIA
ERGOTAMINE
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
ECHA (EC/EINECS)
204-023-9
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
ChEMBL
CHEMBL442
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY